Compare Abeona Therapeutics Inc (ABEO) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while First Trust NASDAQ 100 Technology Index Fund trades at $311.97. Which is the better fit depends on your goals.
| ABEO | QTEC | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $335.74 |
52-Week Low | $4.17 | $207.03 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
QTEC trades at $320.77, up 1.84% with neutral technical signals and bullish moving averages. The ETF provides equal-weighted exposure to Nasdaq-100 technology stocks, recently hitting 52-week highs. Support levels cluster around $313-318 while resistance sits at $324-329. Recent news highlights QTEC's role in tech sector exposure amid AI and chip stock momentum.
The ETF's equal-weight approach diversifies tech sector risk, though concentrated tech exposure remains sensitive to sector volatility. Current technical positioning suggests consolidation near pivot points, with institutional interest balanced by valuation concerns in overheated AI segments. Key risks include sector rotation and macroeconomic pressure on growth stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
